Lasmiditan
Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It is known to target 5-hydroxytryptamine receptor 1F. Reyvow's patent is valid until 2037-12-05 (FDA).
| Trade Name | Reyvow |
|---|---|
| Common Name | Lasmiditan |
| Indication | migraine with aura, migraine without aura |
| Drug Class | Antimigraine (5-HT1 receptor agonists) |
